Efficacy, Safety, & Pharmacokinetics of Candesartan Cilexetil in Hypertensive Paediatric Subjects 6 to < 17 Years of Age

NCT00244595 | Completed Phase 3

• 2 other identifiers: D2451C00001261B
• Study Type: interventional
• Target: 235
• Locations: 4 countries
• Sites: 44

Brief Summary

The objectives of this study are to describe candesartan cilexetil antihypertensive effects in terms of achieved blood pressure and hypertension control rates and the relationship between subject characteristics and antihypertensive efficacy, and between antihypertensive therapy (candesartan cilexetil dose and add-on treatments) and efficacy over a 1 year treatment period in hypertensive children ages 6 to \< 17 years; to describe growth in terms of height and weight in the study population; to describe change in neurocognition as assessed by the Full Scaled IQ score in a subset of study subjects; to determine the pharmacokinetics of candesartan in hypertensive paediatric subjects ages 6 to \< 17 years; and to describe safety including adverse events and adverse events necessitating study drug discontinuation including dose level and dose duration relationships and growth over a 1 year period in hypertensive children age 6 to \< 17 years.

Conditions

Hypertension

Keywords

Pediatric hypertension; Hypertension in children

Outcome Measures

Primary Outcomes (3)

• - Achieved sitting, trough, systolic blood pressure summarized over time and at Week 52 & the mean of the last two measures.

• - The measure of effect is the mean value and the corresponding descriptive statistics.

• - Additional measures include mean diastolic blood pressure, and the proportion of subjects meeting 'controlled' criteria.

Secondary Outcomes (3)

• - Subject and baseline characteristics, antecedent treatment (eg, in 261A, an double-blind placebo-controlled efficacy study that is described elsewhere)

• - The relationship to efficacy measures

• - The relationship of antihypertensive treatment (candesartan cilexetil dose; add on therapy) and achieved blood pressure.

Interventions

candsartan cilexetil DRUG

Eligibility Criteria

• Age: 6 Years - 17 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)

You may qualify if:

• The subjects must have fulfilled the eligibility criteria for and have participated in Study 261A or did not participate in Study 261A but meet the following criteria:
• Diagnosed and untreated hypertension, or
• Diagnosed and treated, but off antihypertensive treatment for at least 2 days with a mean sitting systolic blood pressure and/or sitting diastolic blood pressure ≥ 95th percentile and ≤ 20 mm Hg (systolic) and/or 10 (diastolic) mm Hg above the 95th percentile based on height-adjusted charts for age and gender.
• Females of childbearing potential (post-menarche), must have a negative urine pregnancy test and adhere to a pregnancy prevention method (abstinence, a barrier method plus a spermicidal foam or an oral or implanted contraceptive).
• A signed informed consent by a parent or a legal guardian and an assent form signed by the subject (if applicable).

You may not qualify if:

• Any situation, clinical condition or laboratory abnormality that, in the opinion of the investigator or sponsor, may interfere with the subject's participation in the study or would pose a significant risk to the subject or interfere with the assessment of safety and efficacy endpoints.
• Hypertension secondary to coarctation of the aorta, pheochromocytoma, hyperthyroidism, Cushing's syndrome, or medications (eg: corticosteroids).
• Known history of bilateral renal artery stenosis, unilateral renal artery stenosis or a renal transplant.
• Glomerular filtration rate \< 50 mL/min based on an estimated value using the Schwartz Formula.
• Nephrotic syndrome not in remission.
• Insulin dependent diabetes mellitus.
• Known bleeding, coagulation, or platelet disorder that could interfere with blood sampling.
• Clinically significant valvular heart disease.
• Clinical diagnosis of heart failure.
• Clinically significant arrhythmia (eg, any arrhythmia requiring medical therapy or that causes symptoms).
• Second or third degree AV block.
• Pregnant or breast-feeding an infant.
• Impaired liver function defined as either acute liver disease or chronic liver disease with persistent liver enzyme values greater than 1½ times the upper limit of the reference range for AST or ALT.
• Known hypersensitivity to ARBs.
• Unable to be off antihypertensive medication (diuretics, beta blockers, ACE Inhibitors, etc) for 6-weeks.

Sponsors & Collaborators

• AstraZeneca: lead

Study Sites (44)

Research Site

Phoenix, Arizona, United States

Location

Research Site

Beverly Hills, California, United States

Location

Research Site

Los Angeles, California, United States

Location

Research Site

Madera, California, United States

Location

Research Site

Yuba City, California, United States

Location

Research Site

Newark, Delaware, United States

Location

Research Site

Wilmington, Delaware, United States

Location

Research Site

Miami, Florida, United States

Location

Research Site

Athens, Georgia, United States

Location

Research Site

Augusta, Georgia, United States

Location

Research Site

Chicago, Illinois, United States

Location

Research Site

Park Ridge, Illinois, United States

Location

Research Site

Louisville, Kentucky, United States

Location

Research Site

Ann Arbor, Michigan, United States

Location

Research Site

Jackson, Mississippi, United States

Location

Research Site

Port Gibson, Mississippi, United States

Location

Research Site

St Louis, Missouri, United States

Location

Research Site

Las Vegas, Nevada, United States

Location

Research Site

Paterson, New Jersey, United States

Location

Research Site

Brooklyn, New York, United States

Location

Research Site

New Hyde Park, New York, United States

Location

Research Site

The Bronx, New York, United States

Location

Research Site

Charlotte, North Carolina, United States

Location

Research Site

Winston-Salem, North Carolina, United States

Location

Research Site

Cincinnati, Ohio, United States

Location

Research Site

Cleveland, Ohio, United States

Location

Research Site

Columbus, Ohio, United States

Location

Research Site

Portland, Oregon, United States

Location

Research Site

Philadelphia, Pennsylvania, United States

Location

Research Site

Pittsburgh, Pennsylvania, United States

Location

Research Site

Charleston, South Carolina, United States

Location

Research Site

Beaumont, Texas, United States

Location

Research Site

Houston, Texas, United States

Location

Research Site

Salt Lake City, Utah, United States

Location

Research Site

Charlottesville, Virginia, United States

Location

Research Site

Norfolk, Virginia, United States

Location

Research Site

Charleston, West Virginia, United States

Location

Research Site

Ghent, Belgium

Location

Research Site

Budapest, Hungary

Location

Research Site

Miskolc, Hungary

Location

Research Site

Szeged, Hungary

Location

Research Site

Bratislava, Slovakia

Location

Research Site

Martin, Slovakia

Location

Research Site

Trnava, Slovakia

Location

MeSH Terms

Conditions

Hypertension

Condition Hierarchy (Ancestors)

Vascular Diseases; Cardiovascular Diseases

Study Officials

• AstraZeneca Atacand Medical Science Director, MD

  AstraZeneca

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: October 25, 2005
• First Posted: October 27, 2005
• Study Start: September 1, 2003
• Study Completion: November 1, 2006
• Last Updated: December 9, 2009

Record last verified: 2009-12

Locations

SL (3); BE (1); US (37); HU (3)